Smoking

3
Pipeline Programs
7
Companies
9
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
4 programs
1
1
VareniclinePhase 21 trial
NIC7-001Phase 11 trial
Brief adviceN/A
nicotine replacement therapyN/A1 trial
Active Trials
NCT00352781Completed1,767Est. Aug 2009
NCT01672645Completed277Est. Dec 2015
NCT00635401Completed30Est. Aug 2004
Pierre Fabre
Pierre FabreFrance - Aignan
1 program
1
V0018Phase 21 trial
Active Trials
NCT02359201Completed30Est. Apr 2015
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
Brief adviceN/A1 trial
Active Trials
NCT01589211Terminated347Est. Apr 2013
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
Integrative-omics of the Disordered COPD Small Airway EpitheliumN/A1 trial
Active Trials
NCT02183818Completed42Est. Oct 2020
Mission Therapeutics
Mission TherapeuticsUK - Cambridge
1 program
Monoamine Oxidases in Smoking Pregnant Women and NewbornsN/A1 trial
Active Trials
NCT00169390Completed59Est. Nov 2007
J&
Johnson & JohnsonNEW BRUNSWICK, NJ
1 program
Smoking status as a routine vital signN/A1 trial
Active Trials
NCT00245323Completed2,000Est. Mar 2014
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
Usual brand cigarettesN/A1 trial
Active Trials
NCT02600273CompletedEst. Jun 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Pierre FabreV0018
PfizerVarenicline
PfizerNIC7-001
Allergy TherapeuticsUsual brand cigarettes
Boehringer IngelheimIntegrative-omics of the Disordered COPD Small Airway Epithelium
Heidelberg PharmaBrief advice
Pfizernicotine replacement therapy
Mission TherapeuticsMonoamine Oxidases in Smoking Pregnant Women and Newborns
Johnson & JohnsonSmoking status as a routine vital sign

Clinical Trials (9)

Total enrollment: 4,552 patients across 9 trials

NCT02359201Pierre FabreV0018

Assessment of V0018 1.5 mg Effect on Craving

Start: Feb 2015Est. completion: Apr 201530 patients
Phase 2Completed
NCT00635401PfizerVarenicline

A Study of the Efficacy and Safety of Varenicline in Japanese Smokers Motivated to Quit Smoking

Start: May 2004Est. completion: Aug 200430 patients
Phase 2Completed
NCT01672645PfizerNIC7-001

A Study to Assess the Safety and Tolerability of Different Doses of PF-05402536 and PF-06413367 in Healthy Adult Smokers.

Start: Jun 2012Est. completion: Dec 2015277 patients
Phase 1Completed
NCT02600273Allergy TherapeuticsUsual brand cigarettes

Novel Approaches to Reducing Tobacco Related Harm

Start: Jan 2017Est. completion: Jun 2019
N/ACompleted
NCT02183818Boehringer IngelheimIntegrative-omics of the Disordered COPD Small Airway Epithelium

Integrative-omics of the Disordered COPD Small Airway Epithelium

Start: Apr 2015Est. completion: Oct 202042 patients
N/ACompleted
NCT01589211Heidelberg PharmaBrief advice

Brief Intervention Study for Quitting Smoking

Start: Dec 2011Est. completion: Apr 2013347 patients
N/ATerminated
NCT00352781Pfizernicotine replacement therapy

Stop Smoking Therapy for Ontario Patients

Start: Jul 2006Est. completion: Aug 20091,767 patients
N/ACompleted
NCT00169390Mission TherapeuticsMonoamine Oxidases in Smoking Pregnant Women and Newborns

Monoamine Oxidases in Smoking Pregnant Women and Newborns

Start: Mar 2004Est. completion: Nov 200759 patients
N/ACompleted
NCT00245323Johnson & JohnsonSmoking status as a routine vital sign

Checking Smoking Status as a Routine Vital Sign: A Cluster-Randomized Trial of Its Effect on Cessation Counseling

Start: Nov 2003Est. completion: Mar 20142,000 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

7 companies competing in this space